MaGMa
Financiado
Applying Metabolomics to Unveil follow up treatment biomarkers and Identify Nove...
Applying Metabolomics to Unveil follow up treatment biomarkers and Identify Novel Therapeutic Targets in Glioblastoma
Glioblastoma multiforme (GBM) is the most common and devastating form of malignant brain tumour, containing self-renewing, tumorigenic cancer stem cells (CSCs) that contribute to tumour initiation and therapeutic resistance. The s...
Glioblastoma multiforme (GBM) is the most common and devastating form of malignant brain tumour, containing self-renewing, tumorigenic cancer stem cells (CSCs) that contribute to tumour initiation and therapeutic resistance. The survival of such patients has not improved so much in the last 60 years, and we are still far to get any cure. Therefore, new methods for prognosis and diagnosis are needed, and it could come from better understanding of glioma biology.
The link between cancer and altered metabolism is not new. Many observations were made during the early period of cancer biology research, identifying metabolic changes as a common feature of cancerous tissues to adapt to the necessities of the tumour. GBM comprises several phenotypic subtypes, each with distinguishing hallmark mutations, copy number alterations, epigenetic alterations, and clinical features, generating a different treatment efficacy. We believe that GBM subtypes will produce different patterns in the metabolite fingerprint and moreover the use of treatments will change them.
In the present project we will use a metabolomic approach on a model of human CSCs isolated from fresh surgical tissue, to characterize two of the most extreme phenotypes; proneural and mesenchymal. We will map the tumour metabolite profile and the translation of this knowledge may lead to more personalized therapies. Besides that, we are interested in studying
the metabolite profile of the extracellular vesicles (EV) released by those subtypes. This research effort is not only necessary to map the metabolome of EVs from different origins, but also to elucidate whether or not the metabolites are directly packaged into specific EVs, their possible function in surrounding cells, as the possibility of finding different metabolite profiles characteristic of tumour subtypes and moreover with a differential response to drugs that could be use as biomarkers.
ver más
Duración del proyecto: 25 meses
Fecha Inicio: 2018-02-23
Fecha Fin: 2020-04-03
Fecha Fin: 2020-04-03
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-04-03
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-IF-2017:
Individual Fellowships
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
158K€
Líder del proyecto
FUNDACION UNIVERSITARIA SAN PABLO CEU
No se ha especificado una descripción o un objeto social para esta compañía.
Total investigadores
20
Total investigadores
20